Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma
Anuvrat Sircar(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Lalit Sehgal(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Ken H. Young(The University of Texas MD Anderson Cancer Center), Laura K. Hilton(BC Cancer Agency), Neeraj Jain(The University of Texas MD Anderson Cancer Center), Zijun Y. Xu‐Monette(The University of Texas MD Anderson Cancer Center), Blake R. Peterson(St. Michael's Hospital), Evangelia Chavdoula(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Walter Hanel(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Krysta M. Coyle(Simon Fraser University), Satishkumar Singh(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Lapo Alinari(University of Milan), Jianguo Tao(Moffitt Cancer Center), Parvathi Ranganathan(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Ryan D. Morin(Simon Fraser University), Narendranath Epperla(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Natarajan Muthusamy(The Ohio State University), Philip N. Tsichlis(Molecular Oncology (United States)), Robert A. Baiocchi(The Ohio State University)
Cited by 13
Related Papers
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
|Cancer Cell|2020|1.1k
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
|Nature Medicine|2020|593
Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase
|Proceedings of the National Academy of Sciences|1997|526